Suggested remit: To appraise the clinical and cost effectiveness of adagrasib within its marketing authorisation for treating KRAS G12C mutation positive advanced NSCLC which has been previously treated, or is not suitable for treatment, with platinum based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
 
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 6339

Provisional Schedule

Committee meeting 10 April 2025
Expected publication 02 July 2025

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Stakeholders

Companies sponsors Bristol Myers-Squibb (adagrasib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Asthma and Lung UK
  Black Health Agency for Equality
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Oncogene-Driven Lung Cancer Patient Alliance UK
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  Association of Surgeons of Great Britain and Ireland
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society of Interventional Radiology
  British Thoracic Oncology Group
  British Thoracic Society
  British Transplantation Society
  Cancer Research UK
  Lung Cancer and Mesothelioma Clinical Expert Group
  Lung Cancer Nursing UK
  National Heart and Lung Institute
  NHS Blood and Transplant
  Primary Care Respiratory Society
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Amgen (sotorasib, subject to NICE appraisal)
  Boehringer Ingelheim (nintedanib)
  Hospira (docetaxel)
  Seacross Pharmaceuticals (docetaxel)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services
Relevant research groups Cochrane Lung Cancer Group
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health & Care Research

Timeline

Key events during the development of the guidance:

Date Update
06 September 2024 Invitation to participate
09 July 2024 - 06 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6339
09 July 2024 In progress. Scoping commenced.
19 October 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
26 June 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual